Kayesh Mohammad Enamul Hoque, Kohara Michinori, Tsukiyama-Kohara Kyoko
Department of Microbiology and Public Health, Faculty of Animal Science and Veterinary Medicine, Patuakhali Science and Technology University, Barishal, Bangladesh.
Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Npj Viruses. 2025 Mar 13;3(1):20. doi: 10.1038/s44298-025-00102-3.
Infection with the Zika virus (ZIKV) poses a threat to human health. An improved understanding of the host Toll-like receptor response, disease onset, and viral clearance in vivo and in vitro may lead to the development of therapeutic or prophylactic interventions against viral infections. Currently, no clinically approved ZIKV vaccine is available, highlighting the need for its development. In this study, we discuss the progress in the Zika vaccine, including advances in the use of Toll-like receptor agonists as vaccine adjuvants to enhance vaccine efficacy.
感染寨卡病毒（ZIKV）对人类健康构成威胁。更好地了解宿主Toll样受体反应、疾病发作以及体内外病毒清除情况，可能会促使开发针对病毒感染的治疗性或预防性干预措施。目前，尚无临床批准的寨卡病毒疫苗，这凸显了开发该疫苗的必要性。在本研究中，我们讨论了寨卡疫苗的进展，包括使用Toll样受体激动剂作为疫苗佐剂以提高疫苗效力方面的进展。
